Display options
Share it on

Rev Bras Ortop. 2018 Jul 27;53(5):607-613. doi: 10.1016/j.rboe.2018.07.007. eCollection 2018.

Biometric, histomorphometric, and biochemical profile in atorvastatin calcium treatment of female rats with dexamethasone-induced osteoporosis.

Revista brasileira de ortopedia

Davilson Bragine Ferreira Junior, Virgínia Ramos Pizziolo, Tânia Toledo de Oliveira, Sérgio Luis Pinto da Matta, Mayra Soares Píccolo, José Humberto de Queiroz

Affiliations

  1. Universidade Federal de Viçosa (UFV, Departamento de Bioquímica e Biologia Molecular, Viçosa, MG, Brazil.
  2. Universidade Federal de Viçosa (UFV), Departamento de Biologia Geral, Viçosa, MG, Brazil.

PMID: 30245999 PMCID: PMC6147763 DOI: 10.1016/j.rboe.2018.07.007

Abstract

OBJECTIVE: To assess the effects of atorvastatin calcium in the treatment of dexamethasone-induced osteoporosis.

METHODS: Osteoporosis induction consisted of the administration of an intramuscular dose of 7.5 mg/kg of body weight of dexamethasone, once a week for four weeks, except for the control animals (G1). The animals were divided into the following groups: G1 (control group without osteoporosis), G2 (control group with untreated osteoporosis), G3 (control group with osteoporosis treated with sodium alendronate 0.2 mg/kg) and G4 (group with osteoporosis treated with atorvastatin calcium 1.2 mg/kg). Serum alkaline phosphatase, bone alkaline phosphatase, and biometric and bone histomorphometric assessments were performed after 30 and 60 days of treatment onset.

RESULTS: In relation to the biometric and histomorphometric analyses, at 60 days of treatment, G4 presented bone density (Seedor index), bone trabecular density, and cortical thickness of 0.222 ± 0.004 g/cm, 59.167 ± 2.401%, and 387,501 ± 8573 μm, respectively, with a positive and statistically significant difference (

CONCLUSION: Treatment with atorvastatin calcium demonstrated the ability of this drug to increase osteoblastic activity and bone tissue repair activity, acting differently from alendronate sodium, which demonstrated predominantly antirebsorptive activity.

Keywords: Alendronate; Alkaline phosphatase; Bone histomorphometry; Diphosphonates; Glucocorticoid

References

  1. Natl Sci Rev. 2015 Mar 1;2(1):85-99 - PubMed
  2. Mayo Clin Proc. 2008 Sep;83(9):1032-45 - PubMed
  3. Horm Metab Res. 2008 Nov;40(11):746-51 - PubMed
  4. Endocrinology. 2003 Feb;144(2):681-92 - PubMed
  5. J Bone Miner Res. 1991 Apr;6(4):339-46 - PubMed
  6. Growth Factors. 2015 Apr;33(2):139-48 - PubMed
  7. Osteoporos Int. 2006;17(5):716-23 - PubMed
  8. Vet Clin Pathol. 2003;32(3):101-13 - PubMed
  9. Osteoporos Int. 2007 Oct;18(10):1319-28 - PubMed
  10. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1515-26 - PubMed
  11. Ann N Y Acad Sci. 2006 Apr;1068:367-401 - PubMed
  12. Curr Osteoporos Rep. 2014 Mar;12(1):98-106 - PubMed
  13. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jan;107(1):22-9 - PubMed
  14. Int J Nanomedicine. 2016 Jan 18;11:285-97 - PubMed
  15. Calcif Tissue Int. 2015 Jun;96(6):541-51 - PubMed

Publication Types